SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-004490
Filing Date
2022-03-01
Accepted
2022-03-01 16:06:48
Documents
14
Period of Report
2022-02-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K nltx-20220225.htm   iXBRL 8-K 48159
2 EX-99.1 ex-991xpressreleaseofneole.htm EX-99.1 57704
6 GRAPHIC image_0a.jpg GRAPHIC 14539
  Complete submission text file 0001628280-22-004490.txt   275436

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nltx-20220225.xsd EX-101.SCH 1962
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nltx-20220225_lab.xml EX-101.LAB 24137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nltx-20220225_pre.xml EX-101.PRE 12569
8 EXTRACTED XBRL INSTANCE DOCUMENT nltx-20220225_htm.xml XML 10591
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 22697963
SIC: 2834 Pharmaceutical Preparations